Bright Cell — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Bright Cell is a private, early-stage biotech firm founded in 2018 and headquartered in Boston, with an operational address in Irvine, California. The company is developing a pipeline of stem cell-based therapeutic candidates, some of which are in US FDA-regulated clinical trials, while also offering commercial services in R&D, CDMO, and cell banking. Its business model combines therapeutic development with service revenue, positioning it in the high-growth regenerative medicine market, though it faces significant risks common to pre-revenue biotech ventures, including clinical trial outcomes and funding needs.

Cell TherapyRegenerative Medicine

Technology Platform

Stem cell technology platform applied to therapeutic development, R&D services, CDMO, and cell banking.

Opportunities

The company operates in the high-growth cell therapy and regenerative medicine market.

Its hybrid model offers potential revenue from services to fund high-potential therapeutic development, tapping into both the booming CDMO sector and the vast unmet medical need for new cell-based treatments.

Risk Factors

The company faces high clinical development risk with an undisclosed pipeline, likely requires significant ongoing funding, and operates a potentially resource-intensive dual business model.

Intense competition in both therapeutic development and cell therapy services presents a major challenge.

Competitive Landscape

Bright Cell competes in a crowded field. In therapeutics, it faces numerous biotech and pharma companies advancing stem cell therapies. In services, it competes with large, established CDMOs and specialized cell therapy CROs/CMOs, as well as other stem cell banking providers.

More companies in Cell & Gene Therapy →More companies in United States →